{"id":"placebo-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Systemic adverse events consistent with natural disease progression"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo Vaccine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:40:56.932607+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:41:03.198586+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo Vaccine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:41:03.955241+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108573/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:41:04.439535+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo vaccines are inert formulations used in randomized controlled trials to distinguish genuine therapeutic effects from placebo response and natural disease progression. They allow researchers to measure the incremental benefit of the active vaccine candidate by comparing outcomes between treatment and control groups receiving identical-appearing but inactive preparations.","oneSentence":"A placebo vaccine contains no active therapeutic agent and serves as a control comparator in clinical trials to establish the true efficacy of an investigational vaccine.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:01:39.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:41:06.503078+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Control comparator in clinical trials (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT07495202","phase":"PHASE1","title":"A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JunTop Biosciences Co., LTD","startDate":"2026-03-30","conditions":"Health Volunteer","enrollment":180},{"nctId":"NCT07496450","phase":"PHASE3","title":"A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT05652504","phase":"PHASE1","title":"Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Malaria","enrollment":400},{"nctId":"NCT06745921","phase":"PHASE1","title":"Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-02-24","conditions":"West Nile Viral Infection","enrollment":30},{"nctId":"NCT05419011","phase":"PHASE2","title":"Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-08","conditions":"Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome","enrollment":186},{"nctId":"NCT01915212","phase":"PHASE1","title":"Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-09-26","conditions":"Healthy Volunteers","enrollment":69},{"nctId":"NCT06735209","phase":"PHASE1","title":"First-in-Human PfSPZ-LARC2 Vaccination/CHMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-23","conditions":"Malaria","enrollment":22},{"nctId":"NCT05642429","phase":"PHASE1","title":"Study of AV-1959D, an Amyloid Beta Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute for Molecular Medicine","startDate":"2023-02-27","conditions":"Alzheimer Disease","enrollment":48},{"nctId":"NCT07215858","phase":"PHASE2","title":"BPL-1357 Against H1N1 Influenza Virus Challenge","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Influenza, Human","enrollment":129},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT05921448","phase":"EARLY_PHASE1","title":"Vaccine Pandemic Preparedness Through Airway Immunology Characterization","status":"ACTIVE_NOT_RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2025-05-19","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT07492303","phase":"PHASE1","title":"A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-04-20","conditions":"Pertussis (Whooping Cough), Diphtheria, Tetanus","enrollment":96},{"nctId":"NCT07003984","phase":"PHASE3","title":"A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.","status":"RECRUITING","sponsor":"Bavarian Nordic","startDate":"2025-06-05","conditions":"Chikungunya Virus","enrollment":720},{"nctId":"NCT07300085","phase":"PHASE1","title":"A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cidara Therapeutics Inc.","startDate":"2025-11-08","conditions":"Healthy Participants","enrollment":100},{"nctId":"NCT06210854","phase":"PHASE2","title":"Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05-01","conditions":"HPV Infection","enrollment":48},{"nctId":"NCT06862453","phase":"PHASE1","title":"Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults","status":"NOT_YET_RECRUITING","sponsor":"Sanaria Inc.","startDate":"2026-03","conditions":"Malaria Falciparum","enrollment":58},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT07128615","phase":"PHASE1, PHASE2","title":"A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-04","conditions":"Influenza A","enrollment":405},{"nctId":"NCT04350138","phase":"PHASE2","title":"Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-29","conditions":"Gonococcal Infection","enrollment":2606},{"nctId":"NCT06950645","phase":"PHASE1","title":"The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-03-27","conditions":"Rotavirus Gastroenteritis","enrollment":100},{"nctId":"NCT04649021","phase":"PHASE2","title":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-12-04","conditions":"SARS-CoV-2","enrollment":960},{"nctId":"NCT06652737","phase":"PHASE1","title":"Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanaria Inc.","startDate":"2025-03-04","conditions":"Malaria Falciparum, Malaria Infection","enrollment":75},{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440},{"nctId":"NCT06257212","phase":"PHASE4","title":"Live Vaccines and Innate Immune Training in COPD.","status":"COMPLETED","sponsor":"Josefin Eklöf","startDate":"2024-02-28","conditions":"Trained Innate Immunity, COPD","enrollment":60},{"nctId":"NCT05766904","phase":"PHASE3","title":"Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-04","conditions":"Gonorrhea, Sexually Transmitted Infection","enrollment":150},{"nctId":"NCT07013487","phase":"PHASE3","title":"A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-11","conditions":"Healthy","enrollment":12000},{"nctId":"NCT06669208","phase":"PHASE1","title":"Trial of an Inactivated Chikungunya Virus Vaccine","status":"COMPLETED","sponsor":"Najit Technologies, Inc.","startDate":"2024-11-04","conditions":"Chikungunya Fever, Chikungunya Virus, Chikungunya","enrollment":48},{"nctId":"NCT06719219","phase":"PHASE1","title":"A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2025-01-07","conditions":"Staphylococcus (S.) Aureus Infection","enrollment":129},{"nctId":"NCT06866405","phase":"PHASE3","title":"A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-04-16","conditions":"RSV Infection","enrollment":550},{"nctId":"NCT03462004","phase":"PHASE1","title":"Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-03-05","conditions":"Ebola Virus Disease","enrollment":15},{"nctId":"NCT05547464","phase":"PHASE1, PHASE2","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2023-07-31","conditions":"Tuberculosis","enrollment":497},{"nctId":"NCT05705440","phase":"PHASE3","title":"A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-02-07","conditions":"Respiratory Syncytial Virus Infections","enrollment":3855},{"nctId":"NCT07467707","phase":"PHASE3","title":"An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults","status":"NOT_YET_RECRUITING","sponsor":"Bavarian Nordic","startDate":"2026-05","conditions":"Chikungunya Virus","enrollment":6144},{"nctId":"NCT06692907","phase":"PHASE2","title":"Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-31","conditions":"Escherichia Infection","enrollment":72},{"nctId":"NCT05683457","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-04-05","conditions":"Cytomegalovirus Infection","enrollment":224},{"nctId":"NCT00820820","phase":"NA","title":"IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-01-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":"SARS-CoV-2","enrollment":30000},{"nctId":"NCT06134648","phase":"PHASE1, PHASE2","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-11-01","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus","enrollment":646},{"nctId":"NCT07097012","phase":"PHASE4","title":"Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy","status":"RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-16","conditions":"RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Pregnancy","enrollment":60},{"nctId":"NCT03172975","phase":"PHASE2","title":"Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2018-03-01","conditions":"Hookworm Infections","enrollment":39},{"nctId":"NCT06059391","phase":"PHASE2","title":"CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-12","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia","enrollment":216},{"nctId":"NCT07293065","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)","status":"ACTIVE_NOT_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2025-12-15","conditions":"Herpes Zoster","enrollment":12000},{"nctId":"NCT06253533","phase":"PHASE1","title":"ICVAX as a HIV Therapeutic DNA Vaccine","status":"COMPLETED","sponsor":"Immuno Cure Holding (HK) Limited","startDate":"2023-02-14","conditions":"Human Immunodeficiency Virus, Human Immunodeficiency Virus I Infection","enrollment":45},{"nctId":"NCT06050356","phase":"PHASE1","title":"First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b","status":"ACTIVE_NOT_RECRUITING","sponsor":"Statens Serum Institut","startDate":"2024-03-14","conditions":"Healthy","enrollment":140},{"nctId":"NCT06251024","phase":"PHASE2","title":"Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-02","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers","enrollment":4541},{"nctId":"NCT07220109","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":750},{"nctId":"NCT07365826","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-01-12","conditions":"Pneumococcal Vaccines","enrollment":1300},{"nctId":"NCT07454915","phase":"PHASE2","title":"PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia","status":"NOT_YET_RECRUITING","sponsor":"PapiVax Biotech, Inc.","startDate":"2026-03-01","conditions":"Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16","enrollment":138},{"nctId":"NCT06891950","phase":"PHASE3","title":"Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)","status":"RECRUITING","sponsor":"Butantan Institute","startDate":"2026-03-03","conditions":"Dengue","enrollment":997},{"nctId":"NCT06272812","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.","status":"RECRUITING","sponsor":"International AIDS Vaccine Initiative","startDate":"2025-02-19","conditions":"Tuberculosis (TB)","enrollment":5500},{"nctId":"NCT06973772","phase":"PHASE3","title":"Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.","status":"NOT_YET_RECRUITING","sponsor":"Butantan Institute","startDate":"2026-03-31","conditions":"Dengue, Chikungunya","enrollment":900},{"nctId":"NCT06485258","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2024-08-06","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT06962904","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2025-07-07","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT07379580","phase":"PHASE2","title":"A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-02-20","conditions":"Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection","enrollment":310},{"nctId":"NCT06190509","phase":"PHASE1, PHASE2","title":"Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"LimmaTech Biologics AG","startDate":"2023-12-06","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":251},{"nctId":"NCT06754384","phase":"PHASE1, PHASE2","title":"Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-01-15","conditions":"Hand, Foot, and Mouth Disease (HFMD), Herpangina","enrollment":552},{"nctId":"NCT06036602","phase":"PHASE2","title":"Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2024-07-15","conditions":"Ebola Sudan Virus Disease","enrollment":125},{"nctId":"NCT06680479","phase":"PHASE1","title":"Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-01","conditions":"HIV-1","enrollment":30},{"nctId":"NCT05854381","phase":"PHASE1","title":"To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-09-19","conditions":"HIV I Infection","enrollment":93},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT07445815","phase":"PHASE2","title":"A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody","status":"NOT_YET_RECRUITING","sponsor":"Lanzhou Institute of Biological Products Co., Ltd","startDate":"2026-01-31","conditions":"Rabies (Healthy Volunteers)","enrollment":200},{"nctId":"NCT05089630","phase":"PHASE1, PHASE2","title":"A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-14","conditions":"Cytomegalovirus Infections","enrollment":339},{"nctId":"NCT07431502","phase":"PHASE3","title":"Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2026-05","conditions":"Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Vulvar Site, Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Vaginal Site, Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Penile Site","enrollment":984},{"nctId":"NCT06336317","phase":"PHASE4","title":"Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-24","conditions":"Acute Myocardial Infarction, Cardiovascular Diseases, Inflammatory Response","enrollment":90},{"nctId":"NCT02453048","phase":"PHASE1","title":"Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2015-09","conditions":"Pertussis, Whooping Cough","enrollment":54},{"nctId":"NCT07282665","phase":"PHASE3","title":"A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-10","conditions":"Clostridioides Difficile Associated Disease","enrollment":32000},{"nctId":"NCT06592794","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-24","conditions":"Acute Gastroenteritis, Norovirus Acute Gastroenteritis","enrollment":37864},{"nctId":"NCT06808776","phase":"NA","title":"Stories to Prevent (StoP) HPV Cancers","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2025-11-18","conditions":"Human Papillomavirus Vaccination, Emotions","enrollment":200},{"nctId":"NCT05997264","phase":"PHASE2","title":"Anthrax AV7909 Boost Evaluation Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2023-12-05","conditions":"Anthrax","enrollment":220},{"nctId":"NCT06831812","phase":"PHASE1","title":"Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine","status":"COMPLETED","sponsor":"Nuravax, Inc.","startDate":"2024-06-12","conditions":"Alzheimer Disease, Alzheimer Disease (AD), Alzheimers Disease Prevention","enrollment":16},{"nctId":"NCT03512249","phase":"PHASE2","title":"Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence","status":"COMPLETED","sponsor":"International AIDS Vaccine Initiative","startDate":"2019-01-31","conditions":"Tuberculosis, Pulmonary","enrollment":831},{"nctId":"NCT06080243","phase":"PHASE2","title":"Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-03-19","conditions":"Healthy Women of Child Bearing Potential","enrollment":330},{"nctId":"NCT06179446","phase":"PHASE1","title":"A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-13","conditions":"Grippe, Influenza, Vaccines","enrollment":157},{"nctId":"NCT04704830","phase":"PHASE3","title":"R21/Matrix-M in African Children Against Clinical Malaria","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2021-04-29","conditions":"Malaria","enrollment":4800},{"nctId":"NCT07425821","phase":"PHASE1","title":"A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health","status":"NOT_YET_RECRUITING","sponsor":"International AIDS Vaccine Initiative","startDate":"2026-03","conditions":"Marburg Virus Disease","enrollment":112},{"nctId":"NCT07423000","phase":"PHASE1","title":"A Phase 1 Study of PVT401 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Parvus Therapeutics, Inc.","startDate":"2026-04","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":36},{"nctId":"NCT03866187","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":"Hepatitis B, Chronic","enrollment":236},{"nctId":"NCT07421050","phase":"PHASE1","title":"Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-11-13","conditions":"Influenza, Influenza Vaccine","enrollment":80},{"nctId":"NCT07421037","phase":"PHASE1","title":"Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-11-13","conditions":"Influenza, Influenza Vaccine","enrollment":80},{"nctId":"NCT07399132","phase":"EARLY_PHASE1","title":"A Study of APL-10456-Vaccine","status":"RECRUITING","sponsor":"Apollo Therapeutics Ltd","startDate":"2026-02-16","conditions":"Rhinovirus","enrollment":144},{"nctId":"NCT07385287","phase":"PHASE2","title":"Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults","status":"NOT_YET_RECRUITING","sponsor":"Sanaria Inc.","startDate":"2026-04-04","conditions":"Malaria (Plasmodium Falciparum)","enrollment":180},{"nctId":"NCT00339157","phase":"PHASE2, PHASE3","title":"Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2006-05-11","conditions":"Systemic-Onset Juvenile Idiopathic Arthritis","enrollment":24},{"nctId":"NCT05705427","phase":"PHASE4","title":"The COMBAT HBV Feasibility Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-08-17","conditions":"Hepatitis B, Vertical Transmission of Infectious Disease","enrollment":317},{"nctId":"NCT07418229","phase":"PHASE1","title":"Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-09","conditions":"RSV, mRNA Vaccine","enrollment":60},{"nctId":"NCT07059091","phase":"PHASE2","title":"Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-02-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Allergies","enrollment":334},{"nctId":"NCT05591339","phase":"PHASE4","title":"Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bandim Health Project","startDate":"2023-12-01","conditions":"Diabetes Mellitus, BCG Vaccination Reaction","enrollment":200},{"nctId":"NCT07415252","phase":"PHASE3","title":"SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years","status":"NOT_YET_RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-06-05","conditions":"Varicella (Chickenpox)","enrollment":780},{"nctId":"NCT06665646","phase":"PHASE1","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-14","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT03596801","phase":"PHASE1","title":"Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-06-29","conditions":"RSV Infection","enrollment":60},{"nctId":"NCT06617091","phase":"PHASE1","title":"A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.","status":"RECRUITING","sponsor":"International AIDS Vaccine Initiative","startDate":"2025-07-28","conditions":"HIV","enrollment":120},{"nctId":"NCT07280858","phase":"PHASE1, PHASE2","title":"A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-01-28","conditions":"Healthy Participants, Sarbecovirus","enrollment":368},{"nctId":"NCT06062238","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gates Medical Research Institute","startDate":"2024-03-05","conditions":"Tuberculosis","enrollment":20080},{"nctId":"NCT06551181","phase":"PHASE3","title":"A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-08-05","conditions":"Respiratory Syncytial Virus Infections","enrollment":2621},{"nctId":"NCT07208461","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2025-10-21","conditions":"Respiratory Syncytial Virus Infection Prevention","enrollment":700},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT04639466","phase":"PHASE1, PHASE2","title":"A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection","status":"COMPLETED","sponsor":"GeoVax, Inc.","startDate":"2020-11-19","conditions":"COVID-19 Infection","enrollment":119},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT06803342","phase":"PHASE2","title":"A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2025-06-26","conditions":"Ebola Sudan Virus Disease","enrollment":200},{"nctId":"NCT07300462","phase":"PHASE4","title":"A Post-marketing Observational Study of Oral Cholera Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Shanghai United Cell Biotechnology Co., Ltd","startDate":"2026-03","conditions":"Diarrhea","enrollment":6000},{"nctId":"NCT06615375","phase":"PHASE2","title":"A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine","status":"RECRUITING","sponsor":"LimmaTech Biologics AG","startDate":"2024-11-12","conditions":"Shigellosis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2108573"},"_approvalHistory":[],"publicationCount":77,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Group 1","Group 2","Group 3","Group 4","Group 5"],"phase":"marketed","status":"active","brandName":"Placebo Vaccine","genericName":"Placebo Vaccine","companyName":"Dana-Farber Cancer Institute","companyId":"dana-farber-cancer-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"A placebo vaccine contains no active therapeutic agent and serves as a control comparator in clinical trials to establish the true efficacy of an investigational vaccine. Used for Control comparator in clinical trials (not a therapeutic indication).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:41:06.503078+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}